ArticleBioresources and bioprocessing2026
Bacillus subtilis extracellular vesicles surface-displaying superoxide dismutase attenuate alcoholic liver injury by activating the Nrf2/HO-1 axis.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Alcoholic liver disease (ALD) represents a globally prevalent progressive hepatic disorder with continuously rising incidence. Its pathological mechanisms mainly stem from the direct toxic effects of alcohol metabolites, accompanied by aggravated oxidative stress, lipid overaccumulation and inflammatory infiltration.. While current therapies that act on these pathogenic mechanisms alleviate symptoms, they are often limited by gastrointestinal adverse effects and long-term hepatic metabolic burden. Bacterial extracellular vesicles (BEVs), emerging as natural carriers of bioactive molecules and mediators of intercellular communication, offer a novel hepatoprotective strategy against alcoholic liver injury. Superoxide dismutase (SOD), as a crucial antioxidant, has been extensively verified for its capacity to eliminate free radicals. Here, we leverage the advantages of BEVs and the multiple effects of SOD, utilizing surface display technology to locate SOD in Bacillus subtilis 168-derived EVs (termed SEVs). In vitro simulated digestive fluids experiment confirms the stability and digestive resistance of SEVs, while in vivo biodistribution assays demonstrate the liver-targeting capability. In ethanol-exposed hepatocytes, SEVs significantly attenuate reactive oxygen species (ROS) overproduction and lipid deposition. In a murine ALD model, SEVs administration reduces hepatic steatosis, serum transaminase levels, and inflammatory infiltration. Mechanistically, SEVs activate the Nrf2/HO-1 antioxidant pathway, a key regulator of cellular redox balance and inflammation, thereby counteracting oxidative damage and inflammatory reaction caused by alcohol stimulation. Notably, SEVs exhibit superior biocompatibility without inducing secondary hepatic burden. Our findings emphasize the dual advantages of SEVs as liver-targeted delivery vehicles and multifunctional liver-protective agents, highlighting their translational potential for ALD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.